Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00137085|
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : June 14, 2007
|Condition or disease||Intervention/treatment|
|Fractures Dislocations Abscess Anesthesia Analgesia||Drug: ketamine|
This initial, single-centre feasibility study will have the following specific objectives:
- Comparison of low-dose ketamine with fentanyl as adjunct to propofol-assisted emergency department procedural sedation, with respect to safety and efficacy parameters;
- Pilot of a blinded emergency department sedation and analgesia protocol, including drug doses, concealment techniques, and data collection tools, to determine the feasibility of a subsequent larger, multi-centre trial;
- Determination of the true incidence of the primary outcome measures in the study population, using the study drug administration doses and protocol, such that an accurate sample size may be estimated for a future, adequately-powered, multi-centre trial;
- Validation of a newly-developed ordered, categorical rating scale for the reporting of respiratory and hemodynamic adverse events occurring during emergency department procedural sedation and analgesia.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||124 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation|
|Study Start Date :||September 2004|
|Study Completion Date :||August 2006|
- The primary outcome of interest in this study will be the incidence and severity of adverse events during procedural sedation, characterized by using an ordered, four-point categorical scale of airway, ventilatory and hemodynamic adverse events.
- The secondary outcome measures of this study will be: the incidence and type of individual adverse events listed in the primary outcome
- the dose of propofol administered during the procedure
- times from study drug administration to: beginning of procedure, end of procedure, recovery of appropriate verbal response, Emergency Department discharge, incidence of any adverse event(s)
- successful completion of the procedure
- the operator’s rating of the sedation
- incidence of any adverse drug reaction
- patient visual analogue scale (VAS) ratings of analgesia, amnesia, and general satisfaction.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00137085
|Kingston, Ontario, Canada, K7L 3N6|
|Principal Investigator:||Marco LA Sivilotti, MD, MSc||Queen's University|